Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis

Blood

Volumn 128, Issue 21, 2016, Pages 2533-2537

  Chakraborty, Rikhia ^a,b   Burke, Thomas M ^a,b   Hampton, Oliver A ^b   Zinn, Daniel J ^a,b   Lim, Karen Phaik Har ^a,b   Abhyankar, Harshal ^a   Scull, Brooks ^a   Kumar, Vijetha ^b   Kakkar, Nipun ^b   Wheeler, David A ^b   Roy, Angshumoy ^b   Poulikakos, Poulikos I ^c   Merad, Miriam ^c   McClain, Kenneth L ^a,b   Parsons, D Williams ^a,b   Allen, Carl E ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; COMPLEMENTARY DNA; DNA; FAM73A PROTEIN; LANGERIN; MAP2K1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; RNA; TRANSCRIPTOME; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; ONCOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; DNA SEQUENCE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE DELETION; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INDEL MUTATION; LANGERHANS CELL HISTIOCYTOSIS; MOLECULAR PATHOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; RNA SEQUENCE; SCHOOL CHILD; SOMATIC MUTATION; WHOLE EXOME SEQUENCING; ENZYMOLOGY; FEMALE; GENETICS; INFANT; MALE; METABOLISM; MUTATION; PROTEIN DOMAIN;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; ENZYME ACTIVATION; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; MALE; MUTATION; ONCOGENE PROTEINS, FUSION; PROTEIN DOMAINS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 85015013444     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-08-733790     Document Type: Article

References (26)

1. Allen CE, Parsons DW. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders. Hematol Am Soc Hematol Educ Program. 2015;2015:559-564.
2. Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007-3015.
3. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
4. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2015;212(2):281.
5. Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20):3152-3155.
6. Nelson DS, van Halteren A, Quispel WT, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015;54(6):361-368.
7. Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):775-788.
8. Ross JS, Wang K, Chmielecki J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138(4):881-890.
9. Rollins BJ. Genomic alterations in Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 2015;29(5):839-851.
10. Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154-165.
11. Estep AL, Palmer C, McCormick F, Rauen KA. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One. 2007;2(12):e1279.
12. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210(11):2273-2288.
13. Foster SA, Whalen DM, Özen A, et al. Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2. Cancer Cell. 2016;29(4):477-493.
14. Hanrahan AJ, Schultz N, Westfal ML, et al. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov. 2012;2(1):56-67.
15. Jeck WR, Parker J, Carson CC, et al. Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res. 2014;27(4):653-663.
16. Endicott JA, Noble ME, Johnson LN. The structural basis for control of eukaryotic protein kinases. Annu Rev Biochem. 2012;81:587-613.
17. Chen SH, Zhang Y, Van Horn RD, et al. Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120. Cancer Discov. 2016;6(3):300-315.
18. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673-8677.
19. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-798.
20. Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015;526(7574):583-586.
21. Karoulia Z, Wu Y, Ahmed TA, et al. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell. 2016;30(3):501-503.
22. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
23. Swaika A, Crozier JA, Joseph RW. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther. 2014;8:775-787.
24. Héritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016;34(25):3023-3030.
25. Berres ML, Allen CE, Merad M. Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases. Adv Immunol. 2013;120:127-161.
26. Hyman DM, Diamond EL, Vibat CR, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015;5(1):64-71.